Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The mature European IC device market will grow slightly through 2027, driven largely by continuing increases in procedure volumes, driven largely by continuing increases in procedure volumes resulting from innovations that will allow for the use of PCI in more complex patient cases, and growing penetration of intravascular imaging into PCI procedures. These areas of growth will offset ASP declines due to intense price competition across all market segments.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for IC devices in Belgium, the Netherlands, Sweden, and Switzerland across a 10-year period.
The continued launch of newer devices such as BVS and DCBs will drive a shift in device preference in procedures that have traditionally been performed with DES or BMS.
How will the continued development of second-generation BVS impact the coronary stent market?
How are current recommendations for use dictating adoption of DES, BMS, and BVS for CAD patients?
What is the evolving role of DCBs in PCIs in the current clinical landscape?
What has been impact of the launch of Abbott Laboratories' XIENCE Sierra on the DES market?
Despite overall contraction of the IC device market, the accessory device segment is poised to see slight growth due to an increasing focus on specialty devices for complex PCI.
In which segments of the accessory device market have competitors focused their product development efforts?
How will aggregate ASPs be affected by the emerging market for specialized guidewires, microcatheters, and re-entry and recanalization devices?
What are current clinical practices surrounding CTO-PCI, and how do these practices affect accessory devices used during these procedures?
Who are the specialty device market leaders?
Emerging technologies such as FFRCT, resting-state FFR, and angiography-based FFR will influence the IC diagnostic landscape in Europe.
How will the adoption of FFRCT affect patient volume into cardiac catheterization labs?
How will the emergence of alternative FFR modalities affect the FFR pressure guidewire market?
Already a Client? Log in to access this report.
Michael Tian is a senior analyst within the Cardiovascular Medtech Insights team at Decision Resources Group and is an expert in interventional cardiology, cardiac surgery, vascular access, and interventional oncology device markets. Michael spends much of his time exploring and translating large claims and hospital purchase datasets into intriguing stories within the global MedTech market, and he is always looking for the next challenging question to tackle. Michael holds a in Physiology and Neuroscience from the University of Toronto.